PAS-004 has been well-tolerated, with all treatment-related adverse events (TRAEs) being Grade 1 or 2, no observed cardiac or retinal treatment-related events, and low rates of rash and ...
Favorable Safety Profile Supports Long-Term Chronic Dosing: PAS-004 has been well-tolerated, with all treatment-related adverse events ...
Rory Esler was too young to have bowel cancer, the doctors said. On Saturday, nine months after the 35-year-old’s death, his ...
A new study led by researchers at The University of Texas MD Anderson Cancer Center has identified a way to tailor drug ...
Imagine diagnosing cancer, tracking its progress, and identifying treatment resistance—all from a simple blood sample. Just a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results